#south korean remdesivir study

[quickyblog]

तीन दक्षिण कोरियाई कोविद -19 रोगियों में से एक ने रेमेडिसवीर: अधिकारियों के साथ सुधार दिखाया

तीन दक्षिण कोरियाई कोविद -19 रोगियों में से एक ने रेमेडिसवीर: अधिकारियों के साथ सुधार दिखाया

कोविद -19 के साथ गंभीर रूप से बीमार तीन दक्षिण कोरियाई रोगियों में से एक ने गिलियड साइंसेज इंक के एंटीवायरल रेमेडिसविर दिए जाने के बाद अपनी स्थिति में सुधार दिखाया।

उन्होंने कहा कि यह निर्धारित करने के लिए अधिक शोध की आवश्यकता है कि क्या दवा या अन्य कारक जैसे कि रोगियों की प्रतिरक्षा और अन्य उपचारों में सुधार किया गया था, उन्होंने कहा।

एक अमेरिकी नैदानिक ​​परीक्षण में अंतःशिरा रूप से…

[beardedmrbean]

North Korea is grappling with the spread of Covid in an unvaccinated population, and without access to effective anti-viral drugs people are being advised to try alternative remedies such as drinking herbal tea and gargling salt water.

In early 2020, the country sealed its borders to try to insulate itself from the pandemic.

Its leadership has so far rejected outside medical support.

We've been monitoring state media, which is recommending various traditional treatments to deal with what is referred to as "fever".

Herbal teas

For those not seriously ill, ruling-party newspaper Rodong Sinmun recommended remedies including ginger or honeysuckle tea and a willow-leaf drink.

Tea might soothe some Covid symptoms, such as a sore throat or cough, and help hydration when patients are losing more fluid than normal.

But they are not a treatment for the virus itself.

And the same relief could be found from any hot drink - though ginger and willow leaf may have some extra inflammation- and pain-reducing properties.

Gargling salt water

State media recently interviewed a couple who recommended gargling with salt water morning and night.

A "thousand of tonnes of salt" had been sent to Pyongyang to make an "antiseptic solution", the state news agency reported.

Some studies suggest gargling and nasal rinses with salt water could help combat viruses that cause the common cold.

But there is little evidence they slow the spread of Covid.

Covid is mainly caught by inhaling tiny droplets in the air via the nose as well as the mouth, so gargling attacks only one point of entry.

And once the virus has entered, it replicates and spreads deep into the organs, where no amount of gargling can reach.

Painkillers and antibiotics

State television has advised patients to use painkillers such as ibuprofen as well as amoxicillin and other antibiotics.

Ibuprofen (and paracetamol) can bring down a temperature and ease symptoms such as headache or sore throat but they won't clear the virus or prevent it developing.

Antibiotics, meant for bacterial infections not viruses, are not recommended - and risks developing resistant bugs.

Laboratory research suggests some may slow the spread of some viruses, including Covid but these have not been replicated in the real world.

A study of the antibiotic azithromycin found it made little or no difference to Covid symptoms, the likelihood of hospital admission or death.

There are some approved drugs to prevent people with Covid from ending up in hospital: anti-viral drugs paxlovid, molnupiravir and remdesivir), and antibody therapies which mimic our own immune system.

However, they vary in effectiveness.

A weak health system

North Korea's health system has been set up to offer free medical care from basic services at village level up to specialised treatment in government hospitals (usually in urban centres).

But the economy has contracted in recent years because of sanctions and extreme weather such as droughts.

Closing the country's borders and strict lockdown measures will also have had a damaging impact.

Particularly weak outside Pyongyang, the health system is thought to suffer shortages of personnel, medicines and equipment.

A report for the UN, last year, said: "Some of the pharmaceutical, vaccination and medical-appliance plants do not reach the level of good practice of the WHO [World Health Organization] and do not meet local demand as well."

Many North Korean defectors to South Korea have told of having to pay for medication or finding treatment and drugs limited to privileged members of the ruling party.

But state media says it is now increasing production.

Is North Korea getting help?

North Korea turned down three million Chinese-made doses, last year - and reportedly rejected other offers - under Covax, the global vaccine-sharing scheme.

South Korea says it has had no reply to its offer of vaccines, medical supplies and personnel.

North Korea has reportedly recently sent three planes to collect medical supplies from Shenyang in China.

These had not included "anti-pandemic supplies", the Chinese foreign ministry said, but it was "ready to work with North Korea… in the fight against the coronavirus".

[wordparinternational]

Pharmaceutical Translation in the CoVid-19 Context

Pharmaceutical Translation in the CoVid-19 Context

Ctrl + Alt + Del – 2020

The world bemoans the ill-fated calamity of the CoVid outbreak, which has crippled the economy of the world, taken hundreds of thousands of human lives and relegated millions of people to the confines of their homes. There seems to be no end in sight. While most countries are trying their best to come to terms with the reality and find solutions to revive their economies, the greatest task at hand is finding a lasting medical solution.

Need for International Data Exchange

The pandemic nature of the outbreak has necessitated pharmaceutical translation for the exchange of research and information and for expediting clinical research. The need for is every more relevant considering that each country is at different phases of the outbreak and has unique data to share, which can benefit the rest of the world.

The Race against Time

The need to find medicines and vaccines is pressing. The economic cost of the standstill is heavy, and an extended lockdown has to find an alternative. Clinical trials are being expedited and government and non-government agencies are working in tandem to make things happen quicker, ending established protocols and norms. Medical translation of such data has gained ever more significance in this context.

Clinical Trials for Treatment Drugs

Pharmaceutical translation for clinical studies, trials and medical literature is essential for drugs that are being developed and rolled out for the treatment of CoVid-19. Some of the leading developments are the approvals for Favipiravir and Remdesivir.

Whereas Favipiravir is an oral medication meant for mild to moderate symptoms(https://en.wikipedia.org/wiki/Favipiravir),  Remdesivir is an intravenous injection for treating more severe cases (https://www.pharmaceutical-technology.com/news/glenmark-favipiravir-covid-nod/).

Clinical Trials of Vaccines

There is immense optimism among the scientific fraternity about the development of a vaccine. More than a dozen Covid-19 vaccines  are currently being tested globally in humans. The good news is that CoVid is curable, and hence the science for a vaccine is promising. Most vaccines are in varying stages of trials, and still several months from commercial use.

https://www.hindustantimes.com/india-news/india-s-covid-19-vaccines-ready-for-human-trials-all-you-need-to-know-about-covaxin-and-zycov-d/story-Vbwg9CT9z93jE8etUx8xqL.html

Among the more ambitious projects, the Oxford vaccine is expected to complete its third phase of clinical trials by September 2020. According to the Serum Institute of India, the vaccine is expected to hit the markets for commercial use by the end of this year.

https://www.tribuneindia.com/news/nation/oxford-vaccine-by-yr-end-partner-firm-107843

Another welcome news is that of the indigenous Indian vaccine named Covaxin is all set to undertake clinical trials on a fast track.

https://timesofindia.indiatimes.com/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine/articleshow/75649226.cms

Bharat Biotech International partnered with ICMR to develop an indigenous vaccine for CoVid. There is news abuzz that they are targeting a commercial launch of the vaccine by the 15th August 2020!  https://timesofindia.indiatimes.com/india/covid-19-icmrs-aug-15-deadline-to-vaccine-maker-stirs-a-row/articleshow/76778724.cms

Zydus Cadila have got an approval from the Drugs Controller General of India (DCGI) for human clinical trials too.

https://www.thehindu.com/sci-tech/health/potential-covid-19-vaccine-by-zydus-cadila-gets-dcgi-nod-for-human-clinical-trials/article31977556.ece

International Research and Pharmaceutical Translation

Scientific data is being shared across regional boundaries as a way to extend cooperation in a bid to curb the pandemic. Clinical tests in Japan, Korean and China need to be shared with anglophone and European scientists. Russian researchers need to cooperate with Indian scientists.

Japan, South-Korea, Singapore and Taiwan, who seemed to have effectively tackled the spread in the initial stages, are now going to suffer the onslaught when the rest of the world would have crossed the peak. On the other hand, Greece, Germany, Sweden and Norway have had immense success in Europe while Italy, the UK and Spain suffered a severe setback. In India, while Kerala, Karnataka and Telangana did well in containing the spread, Maharashtra and Delhi were badly affected. The scope of trials, treatment plans and success stories need to be transferred across regional and linguistic communities.

Pharmaceutical Translation at WordPar

During this difficult time, WordPar has been supporting pharmaceutical companies in translating their clinical research documents, e-learning modules and other documents. We have organised a team of specialised medical translators for ALL European, Indian and Asian languages. These translators have the necessary expertise to handle medical and pharmaceutical subjects.

For general information about our translation services please click: https://www.wordpar.com/translation-localization/. To get more details about our expertise in pharmaceutical translation, please read the article at https://www.wordpar.com/medical-pharmaceutical-translation/. Read more about our e-learning localization for medical products here: https://www.wordpar.com/e-learning-localization/.

Medical Interpretation

Social distancing and quarantine norms have added another dimension to the need for remote interpreting. At the same time, the need for medical consultation is increasing too. The requirement for medical interpretation has seen a multi-fold increase during these times. Consumer and marketing research are areas where remote interpretation has increased. Many industries are trying to assess the impact of CoVid on consumer behaviour and are conducting surveys involving remote interpretation.

Technologies such as Skype and Zoom have given an impetus to remote conference interpretation in the medical field. More information about medical interpreting can be read on https://www.wordpar.com/interpretation/.

Reach our Medical Translator Team

For support in pharmaceutical translations in USA and Canada, please mail us at info@wordpar.ca.

For assistance in medical translation in Europe and India, please mail us at info@wordpar.com.

Support for medical research translation for the rest of the world can be requested by writing to admin@wordpar.ca.

We are hopeful and pray that the pandemic will end soon, and we will all return to our normal way of life.

[garudabluffs]

Brand names include Chloroquine FNA, Resochin, Dawaquin, and Lariago.

Malaria drug touted by Trump can be fatally toxic 3/21/2020 

The drug touted by the President Donald Trump as a possible line of treatment against the coronavirus comes with severe warnings in China and can kill in dosages as little as two grams. _ _ local media reported that a Wuhan Institute of Virology study found that the drug can kill an adult just dosed at twice the daily amount recommended for treatment, which is one gram. _ _ _ China’s recommendation to use chloroquine in treatment was quickly followed by a warning.

READ MORE https://www.gazettenet.com/Virus-drug-touted-by-Trump-Musk-can-kill-33461328

COVID-19 In late January 2020 during the 2019–20 coronavirus outbreak, Chinese medical researchers stated that exploratory research into chloroquine and two other medications, remdesivir and lopinavir/ritonavir, seemed to have "fairly good inhibitory effects" on the SARS-CoV-2 virus, which is the virus that causes COVID-19. Requests to start clinical testing were submitted.[2][45] Chloroquine had been also proposed as a treatment for SARS, with in vitro tests inhibiting the SARS-CoV virus.[46] On 19 February 2020, preliminary results found that chloroquine may be effective and safe in treating COVID-19 associated pneumonia.[47] There is evidence to indicate the efficacy of chloroquine phosphate against SARS-CoV-2 in vitro on Vero cells.[2] The Guangdong Provincial Department of Science and Technology and the Guangdong Provincial Health and Health Commission issued a report stating that chloroquine phosphate "improves the success rate of treatment and shortens the length of patient’s hospital stay" and recommended it for people diagnosed with mild, moderate and severe cases of novel coronavirus pneumonia.[48] Chloroquine has been recommended by Chinese, South Korean, French and Italian health authorities for the treatment of COVID-19.[49][50][51][unreliable medical source?] These agencies noted contraindications for people with heart disease or diabetes.[52] In February 2020, both drugs were shown to effectively inhibit COVID-19 in vitro,[2] but a further study concluded that hydroxychloroquine was more potent than chloroquine, with a more tolerable safety profile.[53] Preliminary results from a trial suggested that chloroquine is effective and safe in COVID-19 pneumonia, "improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course."[47]

READ MORE https://en.wikipedia.org/wiki/Chloroquine

[global-news-station]

BENGALURU: India’s government said on Tuesday it has approved Gilead Sciences Inc’s antiviral drug remdesivir for emergency use in treating COVID-19 patients.

Remdesivir is the first drug to show improvement in COVID-19 patients in formal clinical trials. It was granted emergency use authorization by the U.S. Food and Drug Administration last month and has received approval by Japanese health regulators.

“(Remdesivir) approved on June 1 under emergency use with condition for five dose administration,” the Drugs Controller General of India said in an email statement.

The drugmaker did not immediately respond to an email seeking further details.

As of Tuesday, India has 198,706 cases of coronavirus and has recorded 5,598 deaths, health ministry data showed.

Gilead Sciences had on Monday reported that remdesivir showed modest benefit in patients with moderate COVID-19 given a five-day course, while those who received it for 10 days in the study did not fare as well.

European and South Korean authorities are also looking at remdesivir, with South Korean health authorities last Friday saying they would request imports of the drug. Gilead is yet to gain regulatory approval in either market.

The post India approves antiviral drug to treat COVID-19 patients appeared first on ARY NEWS.

https://ift.tt/2Le96aD